Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2248.48% is 2383% below its 5-year average of -90.57%, near the low end of its 5-year range (-2248.48%–-33.90%).
624.62% below its 12-month average of -310.30%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2025 (2025-09-30): -786.63%.
RETURN ON EQUITY (ROE)
-2248.48%
RETURN ON EQUITY (ROE) AVG TTM
-310.30%
RETURN ON EQUITY (ROE) AVG 3Y
-82.63%
RETURN ON EQUITY (ROE) AVG 5Y
-90.57%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-624.62%
CURRENT VS 3Y AVG
-2620.99%
CURRENT VS 5Y AVG
-2382.58%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 539 covered companies
CURRENT VS SECTOR MEDIAN
-5493.23%
vs the sector median at left
Jasper Therapeutics, Inc.
Market Cap
$9.32M
Return on Equity (ROE)
-2248.48%
TTM Avg
-310.30%
3Y Avg
-82.63%
5Y Avg
-90.57%
Market Cap
$9.32M
Return on Equity (ROE)
-7.36%
TTM Avg
-85.10%
3Y Avg
-73.72%
5Y Avg
-96.61%
Market Cap
$9.00M
Return on Equity (ROE)
-317.20%
TTM Avg
510.39%
3Y Avg
317.15%
5Y Avg
239.40%
Market Cap
$9.79M
Return on Equity (ROE)
-440.15%
TTM Avg
-145.56%
3Y Avg
-96.97%
5Y Avg
-42.16%
Market Cap
$10.01M
Return on Equity (ROE)
-189.76%
TTM Avg
-774.75%
3Y Avg
-460.85%
5Y Avg
-442.56%
Market Cap
$10.06M
Return on Equity (ROE)
N/A
TTM Avg
18596.99%
3Y Avg
9182.42%
5Y Avg
7349.85%
Market Cap
$10.09M
Return on Equity (ROE)
-506.63%
TTM Avg
-300.20%
3Y Avg
-300.20%
5Y Avg
-300.20%
Market Cap
$9.95M
Return on Equity (ROE)
-211.76%
TTM Avg
-295.58%
3Y Avg
-182.53%
5Y Avg
-207.81%
Market Cap
$8.48M
Return on Equity (ROE)
-34.67%
TTM Avg
10.89%
3Y Avg
102.13%
5Y Avg
71.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | $9.32M | -2248.48% | -310.30% | -82.63% | -90.57% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.32M | -7.36% | -85.10% | -73.72% | -96.61% |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.00M | -317.20% | 510.39% | 317.15% | 239.40% |
| Ainos, Inc. (AIMD)vs › | $9.79M | -440.15% | -145.56% | -96.97% | -42.16% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $10.01M | -189.76% | -774.75% | -460.85% | -442.56% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | 18596.99% | 9182.42% | 7349.85% |
| Caring Brands, Inc. (CABR)vs › | $10.09M | -506.63% | -300.20% | -300.20% | -300.20% |
| MetaVia Inc. (MTVA)vs › | $9.95M | -211.76% | -295.58% | -182.53% | -207.81% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.48M | -34.67% | 10.89% | 102.13% | 71.00% |
| Lifeward Ltd. (LFWD)vs › | $10.47M | -252.37% | -195.20% | -116.68% | -90.09% |
ROE
-2248.5%
ROA
-269.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -786.63% |
| 2025-06-30 | -386.89% |
| 2025-03-31 | -186.49% |
| 2024-12-31 | -115.56% |
| 2024-09-30 | -75.92% |
| 2024-06-30 | -62.24% |
| 2024-03-31 | -56.46% |
| 2023-12-31 | -82.18% |
| 2023-09-30 | -64.90% |
| 2023-06-30 | -50.28% |
| 2023-03-31 | -39.73% |
| 2022-12-31 | -104.71% |
| 2022-09-30 | -70.50% |
| 2022-06-30 | -42.67% |
| 2022-03-31 | -33.90% |
| 2021-12-31 | -44.07% |
| 2021-09-30 | -40.16% |
| 2021-06-30 | -285.61% |
| 2021-03-31 | -184.31% |
